Abstract:Background Mortality is one of the most fundamental metrics of population health. The role of nutrition in reducing mortality is of great public health interest. High levels of homocysteine (HHcy, in part, due to low folate intake) are known to increase the risk of cardiovascular diseases. However, data are limited on the longitudinal association of HHcy levels with all‐cause mortality in low folate regions such as China. Objective In a population with relatively low folate intake and high rate of HHcy, we aimed to test the hypothesis that HHcy is associated with increased mortality and folic acid therapy can reduce the risk of all‐cause mortality associated with HHcy. We also examined whether the effect may be affected by individual MTHFR (a key enzyme involved in Hcy metabolism) gene C677T polymorphism. Methods We analyzed the data of 20,702 hypertensive adults (age: 59.6 ± 7.5 years) enrolled in the China Stroke Primary Prevention Trial (CSPPT), with measurements for individual baseline serum total Hcy (tHcy) levels and MTHFR C677T genotypes. These participants were randomized to receive 5‐year, double‐blind daily treatment with 10mg enalapril and 0.8mg folic acid (n=10,348) or 10mg enalapril alone (n=10,354). Kaplan‐Meier survival analysis and Cox proportionate hazard model were used to estimate the effect of tHcy levels on all‐cause mortality and to test effect modification by folic acid intervention and MTHFR C677T genotype. Results There were 622 (3%) all‐cause deaths during a mean treatment period of 4.5 years. There was a dose‐response relationship between tHcy quartiles and all‐cause mortality (P for trend<0.001) after adjusting for pertinent covariables. This relationship was stronger among participants with CC or CT genotypes than among those with TT genotype. Compared to the enalapril alone group, enalapril plus folic acid therapy further lowered the risk of all‐cause mortality associated with increased tHcy levels. The risk reduction was more pronounced in participants with CC or CT genotypes. Conclusions In this large‐scale study of population residing in a low folate region, we found that baseline tHcy levels were associated with all‐cause mortality in a dose‐response fashion; and folic acid therapy can lower the all‐cause mortality risk associated with HHcy. Our data suggest that tHcy and MTHFR genotypes may serve as biomarkers for risk stratification and folic acid therapy may offer a simple, inexpensive and safe intervention strategy to reduce mortality among population characterized by low folate intake and high rate of HHcy.

Mortality risk in men is associated with a common mutation in the methylenetetrahydrofolate reductase gene (MTHFR)

Relationship Between Folate and Methylenetetrahydrofolate Reductase Gene C677T Polymorphisms and Acute Myocardial Infarction

5,10-Methylenetetrahydrofolate reductase ( MTHFR ), methionine synthase ( MTRR ), and methionine synthase reductase ( MTR ) gene polymorphisms and adult meningioma risk

Mthfr C677t Polymorphism And Risk Of Congenital Heart Defects: Evidence From 29 Case-Control And Tdt Studies

Homocysteine and All-Cause Mortality in Hypertensive Adults Without Pre-Existing Cardiovascular Conditions: Effect Modification by MTHFR C677T Polymorphism.

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease

The Association of Plasma Homocysteine Concentrations with a 10-Year Risk of All-Cause and Cardiovascular Mortality in a Community-Based Chinese Population

Methylenetetrahydrofolate (MTHFR), the One-Carbon Cycle, and Cardiovascular Risks

Association of methylene tetrahydrofolate reductase (MTHFR) gene polymorphisms with serum folate, cobalanin and homocysteine concentrations in Greek adults

Impact of new mutations in the methylenetetrahydrofolate reductase gene assessed on biochemical phenotypes: a familial study

Impact of Folic-Acid Intervention and Mthfrc677t Gene Polymorphism on All-Cause Mortality Associated with Elevated Serum Homocysteine Levels in Chinese Adults with Hypertension

The Methylenetetrahydrofolate Reductase ( MTHFR ) C677T Polymorphism and Tumor Risk: Evidence from 134 Case–control Studies

Methylenetetrahydrofolate Reductase C677T Polymorphism, Hypertension, and Risks of Stroke: A Prospective Nested Case–control Study

Genetic Variants of Homocysteine Metabolism, Homocysteine, and Frailty - Rugao Longevity and Ageing Study.

Clinical Study on Effect of Common Methylenetetrahydrofolate Reductase Gene Mutation on Coronary Artery Disease in Hypertension

Methylenetetrahydrofolate Reductase C677t Polymorphism, Hypertension And Risk Of Stroke: A Prospective, Nested Case-Control Study

PS042 Risk Factors Associated with Hyperhomocysteinemia Besides Folate in a Chinese Community-Based Population

Association of Methylenetetrahydrofolate Reductase (MTHFR) Rs1801133 (677C>T) Gene Polymorphism with Ischemic Stroke Risk in Different Populations: an Updated Meta-Analysis

Meta Analysis of the Association Between MTHFR C677T Polymorphism and the Risk of Congenital Heart Defects.

Single nucleotide polymorphism of MTHFR rs1801133 associated with elevated Hcy levels affects susceptibility to cerebral small vessel disease